The administration of anti-PD-1 has been shown to enhance the sensitivity of tumors to anti-angiogenic therapy, thereby extending its effectiveness in models of metastatic breast cancer, pancreatic neuroendocrine tumors, and melanoma. This evidence concerns the gene PDCD1 and melanoma.